Related Experiment Video
Updated: May 21, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor
Zihan Chen1, Jiangnan Yu1, Zhikun Guo1
1International Cancer Center, Shenzhen University Medical School, Shenzhen 518054, Guang Dong, China.
Abstract:
With the escalating application of immune checkpoint inhibitors (ICIs) in solid tumors, these therapies have demonstrated clinical benefits but remain hampered by relatively low response rates. Reliable biomarkers to predict ICIs responsiveness are essential for selecting appropriate patients and optimizing therapeutic outcomes. Given the pivotal role of tumor-draining lymph nodes (TDLNs) in orchestrating systemic antitumor immunity, their intrinsic features-such as dynamic organization in T cell subsets and functional status of antigen-presenting cells, hold considerable potential as predictive biomarkers for ICIs. Moreover, the complexity of ICIs-induced responses in TDLNs necessitates integrating multiple biomarkers for accurate prediction. Through continuous refinement of predictive strategies, TDLNs are poised to play an indispensable role in enhancing ICIs efficacy and guiding personalized immunotherapy. Here, we provide a review to discuss the possibility of using the intrinsic features of TDLNs as a predictive marker for ICI therapy.
Insights
Tumor-draining lymph nodes (TDLNs) show promise as predictive biomarkers for immune checkpoint inhibitors (ICIs) in solid tumors. Analyzing TDLN features could improve patient selection and enhance immunotherapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) offer clinical benefits in solid tumors but have limited response rates.
- Predictive biomarkers are crucial for patient selection and optimizing ICI therapy outcomes.
- Tumor-draining lymph nodes (TDLNs) are key in systemic antitumor immunity.
Purpose of the Study:
- To review the potential of intrinsic TDLN features as predictive biomarkers for ICI therapy.
- To explore how TDLN characteristics can guide personalized immunotherapy strategies.
Main Methods:
- Review of existing literature on TDLN biology and ICI response.
- Analysis of TDLN features, including T cell subsets and antigen-presenting cell function.
- Discussion of integrating multiple biomarkers for enhanced predictive accuracy.
Main Results:
- TDLN intrinsic features, such as T cell dynamics and antigen-presenting cell status, show potential as predictive biomarkers.
- The complexity of ICI responses in TDLNs suggests a need for multi-biomarker approaches.
- Refined predictive strategies involving TDLNs could significantly enhance ICI efficacy.
Conclusions:
- TDLNs possess intrinsic features that can serve as valuable predictive markers for ICI therapy.
- Leveraging TDLN characteristics can improve patient stratification and optimize immunotherapy outcomes.
- TDLNs are essential for enhancing ICI efficacy and advancing personalized cancer treatment.
